Literature DB >> 22882598

Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing.

João Conde1, Alfredo Ambrosone, Vanesa Sanz, Yulan Hernandez, Valentina Marchesano, Furong Tian, Hannah Child, Catherine C Berry, M Ricardo Ibarra, Pedro V Baptista, Claudia Tortiglione, Jesus M de la Fuente.   

Abstract

Over the past decade, the capability of double-stranded RNAs to interfere with gene expression has driven new therapeutic approaches. Since small interfering RNA (siRNAs, 21 base pair double-stranded RNA) was shown to be able to elicit RNA interference (RNAi), efforts were directed toward the development of efficient delivery systems to preserve siRNA bioactivity throughout the delivery route, from the administration site to the target cell. Here we provide evidence of RNAi triggering, specifically silencing c-myc protooncogene, via the synthesis of a library of novel multifunctional gold nanoparticles (AuNPs). The efficiency of the AuNPs is demonstrated using a hierarchical approach including three biological systems of increasing complexity: in vitro cultured human cells, in vivo invertebrate (freshwater polyp, Hydra ), and in vivo vertebrate (mouse) models. Our synthetic methodology involved fine-tuning of multiple structural and functional moieties. Selection of the most active functionalities was assisted step-by-step through functional testing that adopted this hierarchical strategy. Merging these chemical and biological approaches led to a safe, nonpathogenic, self-tracking, and universally valid nanocarrier that could be exploited for therapeutic RNAi.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882598     DOI: 10.1021/nn3030223

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  47 in total

1.  Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy.

Authors:  Sanjay Singh
Journal:  Bioimpacts       Date:  2013-01-14

2.  3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine (pytz)-capped silver nanoparticles (TzAgNPs) inhibit biofilm formation of Pseudomonas aeruginosa: a potential approach toward breaking the wall of biofilm through reactive oxygen species (ROS) generation.

Authors:  Poulomi Chakraborty; Sutapa Joardar; Shounak Ray; Papu Biswas; Debasish Maiti; Prosun Tribedi
Journal:  Folia Microbiol (Praha)       Date:  2018-05-31       Impact factor: 2.099

Review 3.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

Review 4.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Authors:  Byungji Kim; Ji-Ho Park; Michael J Sailor
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

5.  Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.

Authors:  João Conde; Nuria Oliva; Natalie Artzi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

Review 6.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

7.  Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells.

Authors:  João Conde; Chenchen Bao; Yeqi Tan; Daxiang Cui; Elazer R Edelman; Helena S Azevedo; Hugh J Byrne; Natalie Artzi; Furong Tian
Journal:  Adv Funct Mater       Date:  2015-06-01       Impact factor: 18.808

8.  Tracking mesenchymal stromal cells using an ultra-bright TAT-functionalized plasmonic-active nanoplatform.

Authors:  Hsiangkuo Yuan; Jose A Gomez; Jennifer S Chien; Lunan Zhang; Christy M Wilson; Shuqin Li; Andrew M Fales; Yang Liu; Gerald A Grant; Maria Mirotsou; Victor J Dzau; Tuan Vo-Dinh
Journal:  J Biophotonics       Date:  2015-09-11       Impact factor: 3.207

9.  Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Authors:  K Roellecke; E L Virts; R Einholz; K Z Edson; B Altvater; C Rossig; D von Laer; K Scheckenbach; M Wagenmann; D Reinhardt; C M Kramm; A E Rettie; C Wiek; H Hanenberg
Journal:  Gene Ther       Date:  2016-05-19       Impact factor: 5.250

Review 10.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.